|本期目录/Table of Contents|

[1]张大启 综述,杨 丽 审校.LRP4抗体阳性的重症肌无力研究进展[J].天津医科大学学报,2016,22(01):87-89.
点击复制

LRP4抗体阳性的重症肌无力研究进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
22卷
期数:
2016年01期
页码:
87-89
栏目:
综述
出版日期:
2016-01-20

文章信息/Info

Title:
-
文章编号:
1006-8147（2016）01-0087-03
作者:
张大启 综述; 杨 丽 审校

（天津医科大学总医院神经内科，天津市神经病学研究所，天津 300052）

Author(s):
-
关键词:
重症肌无力; 低密度脂蛋白受体相关蛋白4; 乙酰胆碱受体;  肌肉特异性酪氨酸激酶
Keywords:
-
分类号:
R746.1
DOI:
-
文献标志码:
A
摘要:
-
Abstract:
-

参考文献/References:

[1]Meriggioli M N, Sanders D B. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity[J].Lancet Neurol,2009,8(5):475

[2]Carr A S, Cardwell C R, Mccarron P O, et al. A systematic review of population based epidemiological studies in Myasthenia Gravis[J].BMC Neurol,2010,10:46

[3]Verschuuren J J, Huijbers M G, Plomp J J, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4[J]. Autoimmun Rev,2013,12(9):918

[4]Maniaol A H, Elsais A, Lorentzen ? R, et al. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population[J].PLoS One,2012,7(5):e36603

[5]Cavalcante P, Cufi P, Mantegazza R, et al. Etiology of myasthenia gravis: innate immunity signature in pathological thymus[J].Autoimmun Rev,2013,12(9):863

[6]Marx A, Pfister F, Schalke B, et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes[J].Autoimmun Rev,2013,12(9):875

[7]Masuda T, Motomura M, Utsugisawa K, et al. Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis[J].J Neurol Neurosurg Psychiatry,2012,83(9):935

[8]Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis[J].J Neurol,2012,259(3):427

[9]Guptill J T, Sanders D B, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts[J].Muscle Nerve, 2011,44(1):36

[10]Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia[J].Neurology,2012,78(3):189

[11]Kawakami Y, Ito M, Hirayama M, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK[J].Neurology,2011,77(20):1819

[12]Klooster R, Plomp J J, Huijbers M G, et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice[J].Brain, 2012,135(Pt 4):1081

[13]Sieb J P. Myasthenia gravis: an update for the clinician[J].Clin Exp Immunol,2014,175(3):408

[14]May P, Woldt E, Matz R L, et al. The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions[J].Ann Med,2007,39(3):219

[15]Hussain M M. Structural, biochemical and signaling properties of the low-density lipoprotein receptor gene family[J].Front Biosci,2001,6:D417

[16]Go G W, Mani A.Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis[J].Yale J Biol Med,2012,85(1):19

[17]Willnow T E, Nykjaer A, Herz J. Lipoprotein receptors: new roles for ancient proteins[J].Nat Cell Biol,1999,1(6):E157

[18]Simon-Chazottes D, Tutois S, Kuehn M, et al. Mutations in the gene encoding the low-density lipoprotein receptor LRP4 cause abnormal limb development in the mouse[J]. Genomics, 2006,87(5):673

[19]Johnson E B, Steffen D J, Lynch K W, et al. Defective splicing of Megf7/Lrp4, a regulator of distal limb development, in autosomal recessive mulefoot disease[J]. Genomics,2006,88(5):600

[20]Cossins J, Belaya K, Zoltowska K, et al. The search for new antigenic targets in myasthenia gravis[J].Ann N Y Acad Sci,2012,1275:123

[21]Barik A, Lu Y, Sathyamurthy A, et al. LRP4 is critical for neuromuscular junction maintenance[J].J Neurosci, 2014, 34(42):13892

[22]Zong Y, Zhang B, Gu S, et al. Structural basis of agrin-LRP4-MuSK signaling[J].Genes Dev,2012,26(3):247

[23]Shen C, Lu Y, Zhang B, et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis[J].J Clin Invest,2013,123(12):5190

[24]Rodríguez Cruz P M, Al-Hajjar M, Huda S, et al. Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis[J].JAMA Neurol, 2015,72 (6): 642

[25]Higuchi O, Hamuro J, Motomura M, et al. Autoantibodies to Low-Density lipoprotein Receptor-Related protein 4 in myasthenia gravis[J].Ann Neurol,2011,69(2):418

[26]Zhang B, Tzartos J S, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis[J].Arch Neurol, 2012,69(4):445

[27]Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis[J].J Autoimmun,2014,52:139

[28]Meriggioli M N, Sanders D B. Muscle autoantibodies in myasthenia gravis: beyond diagnosis[J].Expert Rev Clin Immunol,2012,8(5):427

[29]Yang L, Maxwell S, Leite M I, et al. Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China[J].J Neurol Sci,2011,301(1/2):71

[30]Tsivgoulis G, Dervenoulas G, Kokotis P, et al. Double seronegative myasthenia gravis with low density lipoprotein-4 (LRP4) antibodies presenting with isolated ocular symptoms[J].J Neurol Sci,2014,346(1/2):328

相似文献/References:

[1]孟繁杰 综述,王广舜 审校.胸腺瘤与自身免疫性疾病的研究进展[J].天津医科大学学报,2021,27(02):195.

备注/Memo

备注/Memo:
基金项目 国家自然科学基金资助项目(81171183)

作者简介 张大启(1983-)，男，主治医师，硕士，研究方向：神经免疫；通信作者：杨丽，E-mail：yangli2001@tmu.edu.cn。

更新日期/Last Update: 2016-01-26